clinical trial · NCT01736592
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
Stargardt's DiseaseLong term follow up in all patients who received SAR422459 in previous study TDU13583
brief summary
Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity
started
Dec 14, 2012
primary completion
Aug 29, 2033
completion
Aug 29, 2033
last updated
Jun 12, 2025
detailed description
Patients will be followed for 15 years after completion/early termination from the previous TDU13583 study (NCT01367444).
As the initial TDU13583 study is terminated - recruitment to this LTS13588 study is over with 27 patients enrolled.
official title
An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol